Profile data is unavailable for this security.
About the company
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 is in Phase 1 development is being developed as a potential product intended to target B-cell malignancies and autoimmune diseases, based on a next generation 1XX co-stimulatory domain and the innate advantages of EBV T cells as the foundation for an allogeneic CAR T platform.
- Revenue in USD (TTM)62.39m
- Net income in USD-181.05m
- Incorporated2012
- Employees165.00
- LocationAtara Biotherapeutics Inc2380 Conejo Spectrum St, Suite 200THOUSAND OAKS 91320United StatesUSA
- Phone+1 (805) 623-4244
- Fax+1 (302) 636-5454
- Websitehttps://www.atarabio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DURECT Corp | 8.41m | -15.80m | 39.42m | 47.00 | -- | 7.83 | -- | 4.69 | -0.5283 | -0.5283 | 0.2842 | 0.1623 | 0.2143 | 0.682 | 7.26 | 145,017.20 | -40.25 | -37.34 | -208.53 | -53.44 | 80.80 | 91.83 | -187.84 | -139.11 | 0.797 | -38.83 | 0.7135 | -- | -55.67 | -10.96 | 21.82 | -- | -10.98 | -- |
Reviva Pharmaceuticals Holdings, Inc. | 0.00 | -35.51m | 40.04m | 15.00 | -- | -- | -- | -- | -1.30 | -1.30 | 0.00 | -0.2026 | 0.00 | -- | -- | 0.00 | -356.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -38.92 | -- | -- | -- |
Lantern Pharma Inc | 0.00 | -17.75m | 40.15m | 21.00 | -- | 1.30 | -- | -- | -1.65 | -1.65 | 0.00 | 2.87 | 0.00 | -- | -- | 0.00 | -40.79 | -28.83 | -44.71 | -30.17 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.93 | -- | -- | -- |
Estrella Immunopharma Inc | 0.00 | -6.29m | 40.17m | -- | -- | 9.43 | -- | -- | -0.1687 | -0.1687 | 0.00 | 0.1178 | 0.00 | -- | -- | -- | -168.15 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 34.21 | -- | -- | -- |
OncoCyte Corp | 1.02m | -36.80m | 40.26m | 43.00 | -- | 1.77 | -- | 39.35 | -4.26 | -4.26 | 0.1087 | 1.70 | 0.0126 | -- | 1.14 | 23,790.70 | -44.55 | -35.11 | -49.04 | -39.71 | 8.11 | -- | -3,532.75 | -2,373.36 | -- | -154.75 | 0.0212 | -- | 56.89 | -- | -34.84 | -- | 55.41 | -- |
Clene Inc. | 442.00k | -30.46m | 40.34m | 82.00 | -- | -- | -- | 91.26 | -4.74 | -4.74 | 0.0688 | -0.0783 | 0.0082 | 1.89 | 5.49 | 5,390.24 | -56.31 | -39.43 | -81.90 | -47.32 | 81.00 | -- | -6,890.50 | -5,261.20 | 0.993 | -16.96 | 1.02 | -- | 38.27 | -- | -65.47 | -- | -- | -- |
Calcimedica Inc | 0.00 | -12.59m | 42.57m | 14.00 | -- | 3.08 | -- | -- | -1.88 | -1.88 | 0.00 | 1.29 | 0.00 | -- | -- | 0.00 | -60.97 | -63.99 | -75.48 | -72.71 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 3.51 | -- | -44.35 | -- |
vTv Therapeutics Inc | 1.00m | -20.18m | 43.08m | 16.00 | -- | 2.61 | -- | 43.08 | -6.81 | -6.81 | 0.2701 | 5.47 | 0.029 | -- | 6.54 | 62,500.00 | -73.77 | -111.84 | -170.69 | -- | -- | -- | -2,540.90 | -680.94 | -- | -- | 0.00 | -- | -100.00 | -- | -5.67 | -- | -- | -- |
HST Global Inc | 0.00 | -123.45k | 43.22m | 1.00 | -- | -- | -- | -- | -0.0209 | -0.0209 | 0.00 | -0.0004 | 0.00 | -- | -- | -- | -3,300.80 | -5,836.01 | -- | -- | -- | -- | -- | -- | -- | -27.31 | 5.81 | -- | -- | -- | -0.7858 | -- | -- | -- |
Atara Biotherapeutics Inc | 62.39m | -181.05m | 43.72m | 165.00 | -- | -- | -- | 0.7008 | -39.90 | -39.90 | 13.06 | -22.61 | 0.343 | 0.931 | 42.60 | 277,275.60 | -99.55 | -70.20 | -256.98 | -86.94 | 80.14 | -- | -290.20 | -1,559.33 | 0.2945 | -250.76 | -- | -- | -86.51 | -- | -20.95 | -- | -49.14 | -- |
Provectus Biopharmaceuticals Inc | 683.90k | -2.79m | 44.09m | 4.00 | -- | -- | -- | 64.47 | -0.0067 | -0.0067 | 0.0016 | -0.0179 | 0.5379 | -- | 613.36 | 170,975.00 | -219.43 | -276.33 | -- | -- | -- | -- | -407.97 | -1,667.76 | -- | -9.75 | -- | -- | -43.61 | -- | 12.74 | -- | -- | -- |
LAVA Therapeutics NV | 7.40m | -24.18m | 44.43m | 37.00 | -- | 1.04 | -- | 6.01 | -0.8976 | -0.8976 | 0.2741 | 1.63 | 0.0689 | -- | 3.23 | 199,946.00 | -22.51 | -- | -27.11 | -- | 97.78 | -- | -326.89 | -- | -- | -- | 0.1257 | -- | -65.09 | -- | -31.55 | -- | -- | -- |
Rallybio Corp | 299.00k | -73.88m | 46.88m | 43.00 | -- | 0.5859 | -- | 156.79 | -1.79 | -1.79 | 0.0072 | 1.93 | 0.0025 | -- | -- | 6,953.49 | -61.57 | -- | -67.23 | -- | -- | -- | -24,709.37 | -- | -- | -- | 0.00 | -- | -- | -- | -11.87 | -- | -- | -- |
Vor Biopharma Inc | 0.00 | -118.09m | 47.20m | 168.00 | -- | 0.481 | -- | -- | -1.74 | -1.74 | 0.00 | 1.43 | 0.00 | -- | -- | 0.00 | -60.16 | -45.79 | -64.52 | -48.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.98 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
EcoR1 Capital, LLCas of 31 Mar 2024 | 406.68k | 8.29% |
Redmile Group LLCas of 31 Mar 2024 | 370.53k | 7.56% |
Citadel Advisors LLCas of 31 Mar 2024 | 260.48k | 5.31% |
BofA Securities, Inc.as of 31 Mar 2024 | 257.08k | 5.24% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 196.82k | 4.01% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 196.03k | 4.00% |
Acadian Asset Management LLCas of 30 Jun 2024 | 119.37k | 2.43% |
Vestal Point Capital LPas of 31 Mar 2024 | 112.00k | 2.28% |
AQR Capital Management LLCas of 31 Mar 2024 | 105.02k | 2.14% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 99.56k | 2.03% |